<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; rainbows</title>
	<atom:link href="http://www.tapanray.in/tag/rainbows/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Dwindling Drug Innovation: Declining Image: Unchanged Business And Advocacy Models</title>
		<link>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models</link>
		<comments>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/#comments</comments>
		<pubDate>Mon, 20 Feb 2017 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chasing]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Dwinding]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rainbows]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8099</guid>
		<description><![CDATA[A report of ‘The United States International Trade Commission (USITC)’ released on December 22, 2014 suggested, if tariffs and investment restrictions were fully eliminated, and standards of IP protection were made comparable to the U.S and Western European levels, American &#8230; <a href="http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
